Immunovant, Inc.
IMVT
$22.71
$0.693.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 83.49M | 84.45M | 77.24M | 71.88M | 65.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 487.11M | 471.09M | 438.15M | 405.21M | 352.46M |
| Operating Income | -487.11M | -471.09M | -438.15M | -405.21M | -352.46M |
| Income Before Tax | -462.44M | -445.58M | -412.95M | -382.17M | -322.73M |
| Income Tax Expenses | 2.24M | 1.73M | 890.00K | 539.00K | 279.00K |
| Earnings from Continuing Operations | -464.69 | -447.30 | -413.84 | -382.71 | -323.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -464.69M | -447.30M | -413.84M | -382.71M | -323.01M |
| EBIT | -487.11M | -471.09M | -438.15M | -405.21M | -352.46M |
| EBITDA | -486.69M | -470.69M | -437.77M | -404.87M | -352.17M |
| EPS Basic | -2.83 | -2.85 | -2.74 | -2.62 | -2.22 |
| Normalized Basic EPS | -1.76 | -1.77 | -1.71 | -1.63 | -1.38 |
| EPS Diluted | -2.83 | -2.85 | -2.74 | -2.62 | -2.22 |
| Normalized Diluted EPS | -1.76 | -1.77 | -1.71 | -1.63 | -1.38 |
| Average Basic Shares Outstanding | 658.17M | 631.00M | 606.21M | 584.83M | 582.43M |
| Average Diluted Shares Outstanding | 658.17M | 631.00M | 606.21M | 584.83M | 582.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |